Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs 708.10, up by 14.15 points or 2.04% from its previous closing of Rs 693.95 on the BSE.

The scrip opened at Rs 700.00 and has touched a high and low of Rs 709.00 and Rs. 693.05 respectively. So far 28805 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 696.45 on 02-Jul-2014 and a 52 week low of Rs. 475.60 on 22-Aug-2013.

Last one week high and low of the scrip stood at Rs. 696.45 and Rs. 626.90 respectively. The current market cap of the company is Rs. 146638.40 crore.

The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.06% and 8.29% respectively.

Sun Pharmaceutical Industries is recalling 200 vials of the chemotherapy drug gemcitabine in the United States (US) due to a lack of assurance of sterility. The drug being recalled was manufactured by Sun Pharma's unit Caraco Pharmaceutical Laboratories at its plant in Gujarat.

Meanwhile, the voluntary recall was initiated in April and was classified by the FDA as Class II, implying that use of or exposure to the recalled drug may cause temporary or medically reversible adverse health consequences.

Lastly, this marks Sun Pharma's second drug recall this year. In January, the company started a voluntary recall of about 2,528 bottles of its generic version of diabetes drug Glumetza, after it received a customer complaint that one of the bottles contained tablets of an epilepsy drug.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.